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Osteoclasts are specialized cells that initiate the process of bone resorption, which has two phases, dissolution of the mineral
component and degradation of the organic matrix, in which cathepsin K plays a key role. Cathepsin K inhibitors, which block the
activity of cathepsin on bone resorption lacunae, may be a new therapeutic option in osteoporosis. Odanacatib is a nonpeptidic
biaryl inhibitor of cathepsin K. Two studies have evaluated the eﬃcacy and safety of odanacatib, a phase I study to determine
the dose and a phase II study of safety and eﬃcacy. Due to the long half-life of odanacatib and the similar eﬀects of diﬀerent
doses on bone remodeling markers, a weekly dosage was chosen for the phase II trail, with the best results being obtained with a
dose of 50mg. At 36 months, increases in bone mineral density similar to those produced by other powerful antiresorptive drugs
(zoledronate and denosumab) were observed but there were diﬀerences in the behaviour of bone remodeling markers. Data on
fractures from the phase III trial currently in development are required to conﬁrm these possible advantages.
1.Introduction
Osteoporosis results from alterations in bone remodeling
that cause an imbalance between bone formation and
resorption, with a predominance of resorption resulting
in a reduction in bone strength and the appearance of
fractures. Bone remodeling is a physiological process whose
functionisthepermanentrenovationoftheskeletoninorder
to ensure biomechanically correct bone function and the
regulation of mineral homeostasis. It consists of an initial
phase of bone resorption followed by a phase of formation,
both of which are regulated by general (endocrine) and
local (paracrine) factors. The main endocrine factors include
calciotropic hormones (parathyroid hormone, and vitamin
D) and sexual hormones, mainly estrogens and, to a lesser
extent, androgens. Other hormones, including the thyroid
hormones, growth hormone and leptin play a smaller
role. Local factors include various cytokines and growth
factors that regulate the process, with the inﬂammatory
cytokines IL-1, IL-6, and TNF-α playing a key role [1].
The main regulator and ﬁnal pathway of bone remodeling
is the RANK/RANKL/OPG (Receptor Nuclear Activator
Factor Kappa B/Receptor Nuclear Activator Factor Kappa B
Ligand/Osteoprotegerin) system. During bone remodeling,
bone marrow cells and osteoblasts produce RANKL, which
binds with a transmembrane receptor of the osteoclast
precursor, RANK, causing their diﬀerentiation and activa-
tion. Osteoprotegerin (OPG) is a glycoprotein that acts as
a decoy receptor of RANKL, impeding the activation of
osteoclastogenesis [2].
The most common form of osteoporosis is post-
menopausal, which is initiated by a fall in estrogen levels2 Journal of Osteoporosis
that provokes an imbalance in the TH1/TH2 ratio (type 1
Helper T cells/ type 2 Helper T cells), with a predominance
of TH1 [3]. This is caused by an increase in local levels of IL-
7 which provokes increased concentrations of inﬂammatory
cytokines and RANKL and a reduction in TGF-β,w h i c h
exerts a beneﬁcial eﬀect on bone, producing an increase in
osteoblastic activity and a reduction in apoptosis [4].
Osteoclasts are specialized cells derived from the
mononuclear phagocyte system that initiate the process of
bone resorption in two ways; dissolution of the mineral
component and degradation of the organic matrix. Bone
resorption begins when osteoclasts bond ﬁrmly to the
bone surface through actin-rich podosomes, which form
extensions of the cytoplasm to the interior of the matrix,
creating speciﬁc regions named resorption lacunae. An acid
medium is produced in the interior of the resorption lacunae
that provokes the destruction of the osseous mineral compo-
nent, leaving the organic matrix exposed. Subsequently, the
organic matrix is dissolved by two enzyme groups, matrix
metalloproteinases and cathepsin K, which plays a key role in
degradation of the matrix [5].
Osteoporosis treatment is currently based on two drug
groups, antiresorptive and anabolic agents. Antiresorptive
agents, whose function is to inhibit bone resorption and
generate increased bone mineral density (BMD), were the
ﬁrst to be introduced. The gold standard is treatment with
bisphosphonates, which accelerate the apoptosis of osteo-
clasts and have shown their eﬃcacy in reducing vertebral
and nonvertebral fractures. However, the chronic use of
bisphosphonates may result in both osseous and nonosseous
undesirable eﬀects, and this has led to the search for
alternatives [6], including denosumab, which blocks the
RANK/RANKL/OPG pathway [7]. Other therapeutic targets
have been drugs that block integrins, which play a key role
in the bonding of osteoclasts to bone, and cathepsin K
inhibitors, which block the activity of cathepsin on bone
resorption lacunae [8]. This article reviews current evidence
for the highly selective and speciﬁc cathepsin K inhibitor,
odanacatib, including results from a phase II trial.
2. CathepsinK
Cathepsins are lysosomal proteases that belong to the
papain-like cysteine protease family. Eleven diﬀerent types
have been described (B, C, F, H, K, L, O, S, V, X, and W) with
cathepsin K being the most important with respect to bone
remodeling, since it is a protease with intense collagenase
activity, especially with respect to acid pH, which is essential
to dissolve calcic hydroxyapatite, the main mineral compo-
nent of bone. It degrades the two main types of collagen,
I and II and is predominantly expressed in osteoclasts [9].
Immunoreactivity has also been found in osteoblasts and
osteocytes although its role in these cells is not known. It is
coded by a gene located in chromosome 1q21. Transcription
is initiated by diﬀerent regulating elements, but IL1 and
RANKL can stimulate expression of the gene in osteoclasts
in a process modulated by NF-kB [10]. It is a protein of 329
amino acids that consists of an amino-terminal region of 15
amino acids, a propeptide of 99 amino acids and a catalytic
unit of 215 amino acids [11, 12].
The role of cathepsin K in bone resorption was deter-
mined using evidence from an autosomal recessive osteo-
chondrodysplasia namedpycnodysostosis, averyraredisease
characterized by high BMD, acroosteolysis of the distal
phalanxes, short stature, and cranial deformities with late
closing of the fontanelles. It is caused by a genetic alteration
that produces mutations of the cathepsin K gene causing loss
of function [13]. Studies in mice submitted to nonfunctional
mutations of cathepsin have given rise to diﬀerent models
of osteopetrosis. Pennypacker et al. [14] found increases in
bone volume and in the number and thickness of trabecules
in the distal region of the femur in a group of homozygotic
cathepsin-K-null mice.
Cathepsin K is a key enzyme in the process of bone
resorption and its inhibition is a new therapeutic target for
the treatment of osteoporosis. The antiresorptive treatment
of choice is bisphosphonates, which reduce the risk of
nonvertebral and vertebral fractures. However, bisphospho-
nates may have adverse consequences. They increase the
total number of osteoclasts, although these are described
as hypernucleated, detached proapoptotic and possibly
dysfunctional [15]. In rhesus monkeys, administration of
odanacatibproducedchangesinosteoclastmorphology,with
the accumulation of elongated intracytoplasmic granules,
although the number and size of osteoclast nuclei was not
aﬀected,indicatingnormalfusion.Inadditionthenumberof
osteoclasts increased [16]. In addition bisphosphonates are
associated with osteonecrosis of the mandible, especially in
patients with tumors or diaphyseal fractures of the femur,
although these adverse eﬀects are exceptional [17–19]. The
search for new therapeutic alternatives, such as cathepsin
inhibitors, is interesting. The ideal inhibitor should have a
low molecular weight, exhibit a minimal peptidic character,
be able to bond to cathepsin and have a high selectivity
to inhibit cathepsin K without aﬀecting other cathepsins.
Various inhibitors have been developed including relacatib,
balicatib, MIV-701/710, and odanacatib, the object of this
paper.
3.Odanacatib
Odanacatib is a powerful, reversible nonpeptidic biaryl
inhibitor of cathepsin K that inactivates the proteolytic
activity of cathepsin k. It is synthesized by replacing the P2-
P3 amide bond of an aminoacetronintrile dipeptide 1 with
a phenyl ring. This results in a powerful, selective inhibitor
with the capacity to inhibit cathepsin K in osteoclasts.
The potency and selectivity is due to the presence of the
4-ﬂuoroleucine side chain at the P2 position interacting
within the S2 pocket [8]. Its selectivity is responsible for the
lack of accumulation of undesirable collagen in cutaneous
ﬁbroblasts [20]. A lack of selectivity has led to the retirement
of other inhibitors in phase 2 development due to the
appearance of morphea-like skin lesions [21].
Two studies have been carried out to evaluate the eﬃcacy
and safety of odanacatib, a phase I study to determine the
dose and a phase II study to evaluate the safety and eﬃcacy.Journal of Osteoporosis 3
4. Phase IStudy
This was a randomized, placebo controlled, double-blind
study in post-menopausal women, without menstruation
during the previous three years or during the previous year
andconﬁrmationofanelevatedfolliclestimulatinghormone
level in the postmenopausal range. The study included two
groups, one containing 49 women aged ≤75 years and
another containing 30 women aged ≤70 years. The objective
was to evaluate the safety, tolerability, pharmacokinetics
and pharmacodynamics of odanacatib in order to select
the best dose. The results were measured according to
the response of bone remodeling markers including CTx
(carboxyterminal telopeptide of type I collagen), 1-CTP
(pyridinoline cross-linked carboxyterminal telopeptide of
type 1 collagen), TRAP5b (tartrate-resistant acid phos-
phatase), urinary deoxypyridinoline (uDPD),B S A P( b o n e -
speciﬁc alkaline phosphatase), osteocalcin, and NTx/Cr
(N-terminal telopeptide of type I collagen normalized to
creatinine). CTx and NTx are generated by the catalytic
action of cathepsin on collagen but DPD is not inﬂuenced
by the eﬀect of odanacatib.
The group of 49 women was used to evaluate the weekly
dose.Dosesof5mg,25mg,50mg,and100mgwereusedand
12 women were assigned to the placebo group. The group
of 30 women was used to evaluate the daily dose. Doses of
0.5, 2.5, and 10mg were used, with 6 women assigned to
the placebo group. All doses were administered in fasting
conditions.
Odanacatib had a long half-life of between 66 and 93
hours for all the regimes and doses used. The eﬃcacy
of weekly, and daily doses in modifying the markers was
evaluated. The eﬀect was dose-dependant although not dose
proportional.Reductionsinresorptionmarkersweregreatest
for doses >50mg weekly and doses ≥2.5mg daily. Maximum
suppression was achieved between day 3 and day 5 with the
weekly dose and was maintained until the following dose.
With the daily dose, equivalent suppression was also reached
between day 3 and day 5 and remained stable whilst the drug
was administered. These results suggest greater suppression
with the daily dose but without signiﬁcant diﬀerences with
the weekly dose. Unlike other antiresorptive drugs, no eﬀects
on markers of formation, which remained at levels similar
to placebo, were observed. This decoupling between markers
of resorption and formation suggests a beneﬁcial proﬁle of
odanacatib. No diﬀerences between odanacatib and placebo
were observed in the number of adverse eﬀects [22].
Due to the long half-life of odanacatib and the similar
eﬀects on bone remodeling markers between doses, the
weekly dosage was chosen for the phase II trial.
5.Phase IITrial
This was a double-blind, randomized, placebo-controlled
trial of 12 months duration with an anticipated extension
period of 24 months. It included 399 post-menopausal
women (no menstruation during the previous ﬁve years
or bilateral oophorectomy) aged between 45 and 85 years,
with a T-score <−2 but not less than −3.5 at any site.
Patients were divided into ﬁve groups according to the
dose: placebo, 3mg/weekly, 10mg/weekly, 25mg/weekly and
50mg/weekly. All patients received vitamin D3 (5600 U
weekly) and calcium (500mg/day in the form of calcium
carbonate). The primary objective was changes in bone mass
in the lumbar spine, and secondary objectives were changes
in BMD in other sites, changes in bone remodeling, and
adverse treatment eﬀects.
Of 399 women randomized, 331 (83%) completed 12
months of treatment, and 320 participated in the extension
study, which was completed by 270 patients (70%) at 24
months. No diﬀerences were found between women who
completed or abandoned the study.
The results showed a dose-dependant increase in BMD
in all sites. The greatest increase was obtained with the
highest dose. Weekly administration of 50mg of odanacatib
increasedbonemassby5.7%inthelumbarspine,4.1%inthe
total hip, 4.7% in the femoral neck, 5.2% in the trochanter
and 2.9% in the distal third of the radius at 24 months.
Resorption markers (uNTX/Cr, sCTx, and uDPD) fell in
a dose-dependant manner from the beginning of treatment
and remained reduced during the ﬁrst six months, after
which they increased and the diﬀerences with placebo disap-
peared. Only the 50mg dose showed statistically signiﬁcant
reductions in comparison with placebo. Bone formation
markers showed no diﬀerences with placebo except for the
50mg group, in which bone serum alkaline phosphatase
(BSAP) and type I procollagen N-terminal propeptide
(PINP) decreased initially but then gradually increased, with
signiﬁcant diﬀerences with placebo being observed for both
at month 12 and month 24. Adverse eﬀects were similar in
both groups without signiﬁcant diﬀerences. Bone biopsies
were carried out in 28 patients and showed no adverse
histologic eﬀects [23]. The histologic eﬀects of odanacatib
were evaluated in a study carried out in ovariectomized
monkeys in which the bone histomorphometry of the
femoral neck was analyzed. In addition to an increase in
BMD, diﬀerent behaviour between cortical and trabecular
bone was observed. In the trabecular bone, the behaviour
was similar to established anticatabolic agents, inhibiting
bone remodeling whereas in cortical bone increased bone
formation was observed due to stimulation of periosteal
apposition [24].
The results of the extension of the phase II study to
36 months have recently been reported. This included 189
women who were randomized to odanacatib 50mg and
placebo weekly. The study was completed by 169 women
(89%). In the odanacatib group, BMD continued to increase
(lumbar spine 7.5%, total hip 5.5%, femoral neck 5.5% and
trochanter 7.4%). The urine NTX resorption marker was
50% lower compared with placebo, whereas there were no
diﬀerences in the BSAP formation marker. At three years,
formation markers were not only not reduced but in fact
increased by 18% over baseline values. Table 1 shows the
evolution of the markers. Patients in the placebo group lost
bone mass although this remained above initial values and
normal values of markers were re-established. This suggests
that odanacatib continues to have an eﬀect at three years and
that the eﬀect is rapidly reversible [25].4 Journal of Osteoporosis
Table 1: Eﬀect of 50mg of odanacatib on formation markers and
resorption at 12, 24, and 36 months.
12 months 24 months 36 months
BSAP −18% −15% +18%
NTx/Cr −60.2% −51.8% −50%
CTx −60% −45% −24%
NTx/Cr: N-terminal telopeptide of type I collagen normalized to creatinine.
BSAP: bone-speciﬁc alkaline phosphatase.
CTx: carboxyterminal telopeptide of type I collagen.
The phase I study showed the pharmacodynamics of
odanacatib, with a prolonged half-life that permits weekly
administration. No signiﬁcant diﬀerences was observed
betweenthedailyandweeklydoseinthesuppressionofbone
resorption markers. There were no diﬀerences in adverse
eﬀects between placebo and odanacatib. Taking these data
into account, the phase II trial used the weekly dosage,
achieving the best eﬀects with a dose of 50mg. At 36
months, increases in BMD similar to those of most powerful
antiresorptive agents (zoledronate and denosumab) [6, 26]
were observed, but with diﬀerences in the behaviour of
bone remodeling markers. Decoupling between markers of
formation and resorption were observed in tandem with
increases in the therapeutic window. There was a smaller
reduction in markers of resorption in comparison with other
powerful antiresorptive agents but, in turn, the reduction in
levels of formation markers was much smaller.There are no
dataonfractures,akeyelementindemonstratingtheeﬃcacy
of a drug against osteoporosis. To clarify this point, a study
(ClinicalTrials.gov registration number: NCT00529373) is
ongoing, with results expected in 2012. This is a clinical, ran-
domized, double-blind, trial with 16,000 patients. The target
population is postmenopausal osteoporotic women aged
≥65 years not previously treated for osteoporosis. Patients
with metabolic bone diseases other than osteoporosis or
with previous hip fracture will not be included. Odanacatib
at a dose of 50mg/weekly will be used and placebo will
include calcium and vitamin D. The primary objective of the
study is the reduction in osteoporotic fractures (vertebral,
nonvertebral, and hip).
In conclusion, odanacatib is a cathepsin K inhibitor
whose mechanism of action diﬀers from that of other
antiresorptive agents. It does not reduce the number of
osteoclasts and does not alter their function, thereby oﬀering
theoretical advantages over bisphosphonates. The results of
the phase III trial currently in development are required to
conﬁrm these possible advantages.
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